Metastatic Castrate Resistant Prostate Cancer
9
1
1
3
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
33.3%
3 terminated out of 9 trials
50.0%
-36.5% vs benchmark
11%
1 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
MGC018 With or Without MGA012 in Advanced Solid Tumors
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer
A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)